Jaguar animal health exhibiting at the june 23-25 american college of veterinary internal medicine (acvim) forum as part of ongoing commercial launch activities for canalevia-ca1

Canalevia®-ca1, which received conditional approval from the fda on december 21, 2021, is the first and only treatment for chemotherapy-induced diarrhea (cid) in dogs to receive any type of approval from the fda san francisco, ca / accesswire / june 21, 2022 / jaguar health, inc. (nasdaq:jagx), under its jaguar animal health tradename for the veterinary market, today announced that the company is exhibiting at the american college of veterinary internal medicine (acvim) forum, which takes place june 23 - 25, 2022 in austin, tx, as part of ongoing commercial launch activities for canalevia-ca1 (crofelemer delayed-release tablets). canalevia-ca1, the company's fda conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (cid) in dogs, is now available from multiple leading veterinary distributors in the u.s. jaguar animal health is sponsoring the two below events at the acvim forum: oncology specialty symposium lunch & business meeting: wednesday, june 22, 2022, 12:00 - 2:00 ct, hilton austin grand ballroom g scientific session: tolerability and pharmacokinetic parameters for anticancer agents in dogs: friday, june 24, 2022, 11:00 - 11:30 ct, austin convention center 16ab jaguar animal health is showcasing canalevia-ca1 at exhibit booth number 521 at the acvim forum.
JAGX Ratings Summary
JAGX Quant Ranking